MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM, UNCLASSIFIABLE
Clinical trials for MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM, UNCLASSIFIABLE explained in plain language.
Never miss a new study
Get alerted when new MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM, UNCLASSIFIABLE trials appear
Sign up with your email to follow new studies for MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM, UNCLASSIFIABLE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for rare blood cancers: fedratinib shows promise in early trial
Disease control CompletedThis study tested a drug called fedratinib in 25 adults with rare blood cancers (MDS/MPN and CNL). The goal was to see if the drug could shrink the spleen and improve blood counts. While not a cure, the treatment aims to control the disease and reduce symptoms.
Matched conditions: MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM, UNCLASSIFIABLE
Phase: PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New Two-Step transplant shows promise for blood cancer patients
Disease control CompletedThis study tested a two-step stem cell transplant for people with blood cancers like leukemia and lymphoma. First, patients received low-dose chemotherapy and radiation to prepare their bodies. Then, they got donor stem cells followed by drugs to prevent the donor cells from atta…
Matched conditions: MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM, UNCLASSIFIABLE
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Drug cocktail shows promise against rare bone marrow cancers
Disease control CompletedThis study tested a combination of two drugs, ruxolitinib and azacytidine, in 121 people with myelofibrosis or related blood cancers. The goal was to see if the combo could shrink tumors or improve blood counts. While the treatment aims to control the disease, it is not a cure, a…
Matched conditions: MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM, UNCLASSIFIABLE
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC